ArticleNeurologia medico-chirurgica2025
Volume and Location Analysis of Intracerebral Hemorrhage for the Appropriate Use of Andexanet Alfa.
Article in Neurologia medico-chirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Andexanet alfa was approved as a reversal agent for Factor Xa inhibitors in patients with uncontrolled or life-threatening bleeding, such as intracerebral hemorrhage. However, its use in cases of small hemorrhages remains controversial. This study determined the appropriate use of andexanet alfa on the basis of hematoma volume and location analysis. The study included consecutive patients with intracerebral hemorrhage who took Factor Xa inhibitors between January 2020 and December 2024. Individuals receiving standard care (January 2020-June 2022) and those being administered andexanet alfa (July 2022-December 2024) were compared and classified by hematoma volume (<5 mL, 5-30 mL, and >30 mL). Sixty-one patients were enrolled, with 27 and 34 patients receiving standard care and andexanet alfa care, respectively.Excellent hemostasis (hematoma increase <20%) and preserved neurological findings (National Institutes of Health Stroke Scale change <4) were achieved in patients treated with andexanet alfa compared with patients who received standard care (p = 0.0007, p = 0.004). For middle-sized (5-30 mL) and large-sized (>30 mL) hematomas, the rate of patients with excellent hemostasis in andexanet alfa care was significantly higher than that of patients in standard care (p = 0.032, p = 0.035). Among small hematomas, those in the thalamus or brainstem were significantly associated with neurological deterioration due to hematoma expansion. Andexanet alfa prevented hematoma expansion in these regions of small hematomas (p = 0.0285). In conclusion, small hematomas located in deep regions such as the thalamus or brainstem and bigger than those in any location should be considered for treatment with andexanet alfa as a reversal agent of Factor Xa inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.